These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 34637343)
1. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343 [No Abstract] [Full Text] [Related]
2. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. Weiss MD; Surman C; Khullar A; He E; Cataldo M; Donnelly G CNS Drugs; 2021 Jun; 35(6):667-679. PubMed ID: 34057707 [TBL] [Abstract][Full Text] [Related]
3. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529 [TBL] [Abstract][Full Text] [Related]
4. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. Weiss MD; Surman C; Khullar A; Owens J; He E; Cataldo M; Donnelly G J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):623-630. PubMed ID: 34714112 [No Abstract] [Full Text] [Related]
5. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study. Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921 [No Abstract] [Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903 [No Abstract] [Full Text] [Related]
9. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. Weiss MD; Childress AC; Donnelly GAE J Atten Disord; 2021 Aug; 25(10):1417-1428. PubMed ID: 31916473 [No Abstract] [Full Text] [Related]
10. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989 [TBL] [Abstract][Full Text] [Related]
11. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C; CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922 [TBL] [Abstract][Full Text] [Related]
12. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder. Mattingly G; Arnold V; Yan B; Yu M; Robertson B J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468 [No Abstract] [Full Text] [Related]
13. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943 [TBL] [Abstract][Full Text] [Related]
14. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456 [TBL] [Abstract][Full Text] [Related]
15. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study. Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680 [TBL] [Abstract][Full Text] [Related]
18. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder. Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560 [No Abstract] [Full Text] [Related]
19. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study. Ginsberg Y; Arngrim T; Philipsen A; Gandhi P; Chen CW; Kumar V; Huss M CNS Drugs; 2014 Oct; 28(10):951-62. PubMed ID: 25183661 [TBL] [Abstract][Full Text] [Related]
20. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]